Compare Nokia Corp (NOK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Nokia Corp trades at $10.82 (market cap $59.77B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× Nokia Corp's market cap, and Nokia Corp pays a 1.53% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NOK | VRTX | |
|---|---|---|
Market Cap | $59.77B | $134.06B |
Sector | Technology | Health |
52-Week High | $16.83 | $557.96 |
52-Week Low | $4.51 | $376.62 |
Enterprise Value | $57.71B | $128.18B |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% on the day, supported by a bullish technical signal and positive momentum from AI-driven network infrastructure growth. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with revenue stabilizing around $20 billion annually. Analyst sentiment is predominantly bullish, with 61.5% recommending Buy, amid news of its return to the Euro Stoxx 50 index and expansion in Saudi AI research.
The outlook is cautiously optimistic, driven by AI and cloud demand, but risks include competitive pressures, volatile cash flow, and high valuation multiples. Investment opportunity hinges on execution of growth initiatives, while shareholders face exposure to telecom sector volatility and margin challenges.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
